PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Alzamend Neuro, Inc. (ALZN)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS02262M3088
CUSIP02262M308
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$4.64M
EPS-$1.82
PE Ratio17.68
PEG Ratio1.17
EBITDA (TTM)-$12.35M
Year Range$0.65 - $11.91
Target Price$21.00
Short %0.90%
Short Ratio0.47

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Alzamend Neuro, Inc.

Popular comparisons: ALZN vs. SAVA

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Alzamend Neuro, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%20.00%NovemberDecember2024FebruaryMarchApril
-99.65%
19.43%
ALZN (Alzamend Neuro, Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period

Alzamend Neuro, Inc. had a return of -20.31% year-to-date (YTD) and -91.56% in the last 12 months.


PeriodReturnBenchmark
Year-To-Date-20.31%6.33%
1 month-29.78%-2.81%
6 months-75.37%21.13%
1 year-91.56%24.56%
5 years (annualized)N/A11.55%
10 years (annualized)N/A10.55%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
2024-3.37%6.51%9.17%
2023-9.54%-50.75%-30.90%-26.45%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of ALZN is 5, indicating that it is in the bottom 5% of the market in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.

The Risk-Adjusted Performance Rank of ALZN is 55
Alzamend Neuro, Inc.(ALZN)
The Sharpe Ratio Rank of ALZN is 55Sharpe Ratio Rank
The Sortino Ratio Rank of ALZN is 11Sortino Ratio Rank
The Omega Ratio Rank of ALZN is 22Omega Ratio Rank
The Calmar Ratio Rank of ALZN is 33Calmar Ratio Rank
The Martin Ratio Rank of ALZN is 1515Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Alzamend Neuro, Inc. (ALZN) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


ALZN
Sharpe ratio
The chart of Sharpe ratio for ALZN, currently valued at -1.01, compared to the broader market-2.00-1.000.001.002.003.00-1.01
Sortino ratio
The chart of Sortino ratio for ALZN, currently valued at -2.89, compared to the broader market-4.00-2.000.002.004.006.00-2.89
Omega ratio
The chart of Omega ratio for ALZN, currently valued at 0.67, compared to the broader market0.501.001.500.67
Calmar ratio
The chart of Calmar ratio for ALZN, currently valued at -0.92, compared to the broader market0.001.002.003.004.005.006.00-0.92
Martin ratio
The chart of Martin ratio for ALZN, currently valued at -1.27, compared to the broader market0.0010.0020.0030.00-1.27
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 1.91, compared to the broader market-2.00-1.000.001.002.003.001.91
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 2.77, compared to the broader market-4.00-2.000.002.004.006.002.77
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.33, compared to the broader market0.501.001.501.33
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.46, compared to the broader market0.001.002.003.004.005.006.001.46
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 7.61, compared to the broader market0.0010.0020.0030.007.61

Sharpe Ratio

The current Alzamend Neuro, Inc. Sharpe ratio is -1.01. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00NovemberDecember2024FebruaryMarchApril
-1.01
1.91
ALZN (Alzamend Neuro, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Alzamend Neuro, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%NovemberDecember2024FebruaryMarchApril
-99.65%
-3.48%
ALZN (Alzamend Neuro, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Alzamend Neuro, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Alzamend Neuro, Inc. was 99.67%, occurring on Apr 19, 2024. The portfolio has not yet recovered.

The current Alzamend Neuro, Inc. drawdown is 99.65%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.67%Jun 16, 2021716Apr 19, 2024

Volatility

Volatility Chart

The current Alzamend Neuro, Inc. volatility is 22.51%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%50.00%NovemberDecember2024FebruaryMarchApril
22.51%
3.59%
ALZN (Alzamend Neuro, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Alzamend Neuro, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items